Clinical relapse and resistance to Imatinib has been shown to develop rapidly in the advanced phases of CML and Ph+ ALL patients mainly due to Bcr-Abl-dependent mechanisms such as amplification or mutations in the Abl portion of the Bcr-Abl gene. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.